Coherus BioSciences Inc. [CHRS] Stock trading around $14.14 per share: What’s Next?

Coherus BioSciences Inc. [NASDAQ: CHRS] stock went on a downward path that fall over -6.54% on Monday, amounting to a one-week price decrease of less than -0.98%. The company report on May 8, 2021 that Coherus BioSciences to Present at the Bank of America Health Care Conference.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), announced that senior management will present at the upcoming Bank of America Health Care Conference on Wednesday, May 12, 2021 at 1:15 p.m. EST / 10:15 a.m. PST.

The audio portion of the Company presentation will be available on the investors page of the Coherus BioSciences website at

Over the last 12 months, CHRS stock dropped by -14.92%. The average equity rating for CHRS stock is currently 2.00, trading closer to a bullish pattern in the stock market.

The market cap for the stock reached $983.30 million, with 72.83 million shares outstanding and 67.00 million shares in the current float. Compared to the average trading volume of 1.08M shares, CHRS stock reached a trading volume of 1333642 in the most recent trading day, which is why market watchdogs consider the stock to be active.

Guru’s Opinion on Coherus BioSciences Inc. [CHRS]:

BofA Securities have made an estimate for Coherus BioSciences Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on July 16, 2020. While these analysts kept the previous recommendation, SunTrust raised their target price to Buy. The new note on the price target was released on April 17, 2020, representing the official price target for Coherus BioSciences Inc. stock. On August 02, 2019, analysts increased their price target for CHRS shares from 25 to 27.

The Average True Range (ATR) for Coherus BioSciences Inc. is set at 0.65, with the Price to Sales ratio for CHRS stock in the period of the last 12 months amounting to 2.22. The Price to Book ratio for the last quarter was 8.08, with the Price to Cash per share for the same quarter was set at 5.74. Price to Free Cash Flow for CHRS in the course of the last twelve months was 7.21 with Quick ratio for the last quarter at 2.20.

CHRS Stock Performance Analysis:

Coherus BioSciences Inc. [CHRS] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.98. With this latest performance, CHRS shares dropped by -1.74% in over the last four-week period, additionally sinking by -20.70% over the last 6 months – not to mention a drop of -14.92% in the past year of trading.

Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CHRS stock in for the last two-week period is set at 45.50, with the RSI for the last a single of trading hit 45.25, and the three-weeks RSI is set at 45.23 for Coherus BioSciences Inc. [CHRS]. The present Moving Average for the last 50 days of trading for this stock 14.76, while it was recorded at 14.22 for the last single week of trading, and 17.22 for the last 200 days.

Insight into Coherus BioSciences Inc. Fundamentals:

Operating Margin for any stock indicates how profitable investing would be, and Coherus BioSciences Inc. [CHRS] shares currently have an operating margin of +1.24 and a Gross Margin at +47.30. Coherus BioSciences Inc.’s Net Margin is presently recorded at -0.10.

Return on Total Capital for CHRS is now -0.36, given the latest momentum, and Return on Invested Capital for the company is -0.37. Return on Equity for this stock declined to -0.49, with Return on Assets sitting at -0.20. When it comes to the capital structure of this company, Coherus BioSciences Inc. [CHRS] has a Total Debt to Total Equity ratio set at 33.17. Additionally, CHRS Total Debt to Total Capital is recorded at 24.91, with Total Debt to Total Assets ending up at 13.59. Long-Term Debt to Equity for the company is recorded at 32.05, with the Long-Term Debt to Total Capital now at 24.07.

Reflecting on the efficiency of the workforce at the company, Coherus BioSciences Inc. [CHRS] managed to generate an average of -$88 per employee. Receivables Turnover for the company is 52.47 with a Total Asset Turnover recorded at a value of 1.95.Coherus BioSciences Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.20 and a Current Ratio set at 2.40.


With the latest financial reports released by the company, Coherus BioSciences Inc. posted 0.7/share EPS, while the average EPS was predicted by analysts to be reported at 0.33/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 112.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CHRS. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Coherus BioSciences Inc. go to 2.20%.

Coherus BioSciences Inc. [CHRS] Insider Position Details

There are presently around $1,130 million, in the hands of institutional investors. The top three institutional holders of CHRS stocks are: BLACKROCK INC. with ownership of 11,210,180, which is approximately 6.476% of the company’s market cap and around 0.30% of the total institutional ownership; TEMASEK HOLDINGS (PRIVATE) LTD, holding 7,381,116 shares of the stock with an approximate value of $104.37 million in CHRS stocks shares; and JPMORGAN CHASE & CO, currently with $73.47 million in CHRS stock with ownership of nearly 4.896% of the company’s market capitalization.

Get the hottest stocks to trade every day before the market opens 100% free. Click here now.

Positions in Coherus BioSciences Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 111 institutional holders increased their position in Coherus BioSciences Inc. [NASDAQ:CHRS] by around 7,216,111 shares. Additionally, 93 investors decreased positions by around 14,501,687 shares, while 27 investors held positions by with 58,194,742 shares. The mentioned changes placed institutional holdings at 79,912,540 shares, according to the latest SEC report filing. CHRS stock had 35 new institutional investments in for a total of 1,836,326 shares, while 27 institutional investors sold positions of 6,267,181 shares during the same period.

Share on facebook
Share on twitter
Share on linkedin
Share on skype
Share on reddit

Leave a Comment

Your email address will not be published. Required fields are marked *

Get The Best Stocks To Trade Every Day!

Join now to get the pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam